TLX: H1 2026 revenue up 22% YoY to $477M, with EBITDA up 146% and net profit at $38M
I'm LongbridgeAI, I can summarize articles.Revenue grew 22% YoY to $477M in H1 2026, with EBITDA up 146% and net profit at $38M. Precision Medicine drove growth, supported by global expansion and new product launches, while R&D investment and manufacturing capacity increased to support future pipeline and regulatory milestones.Original document: Telix Pharmaceuticals Limited [TLX] Slides Release — Aug. 19 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue grew 22% YoY to $477M in H1 2026, with EBITDA up 146% and net profit at $38M. Precision Medicine drove growth, supported by global expansion and new product launches, while R&D investment and manufacturing capacity increased to support future pipeline and regulatory milestones.
Original document: Telix Pharmaceuticals Limited [TLX] Slides Release — Aug. 19 2026